SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Issues journals

Medical Radiology and Radiation Safety. 2017. Vol. 62. No. 1. P. 12-19

DOI: 10.12737/25029

Dioxide plutonium-239 in the lung. Report 1: Metabolism 239PuO2 with intratracheal administration

I.K. Belyaev, A.S. Samoylov, E.S. Zhorova, V.S. Kalistratova, I.M. Parfenova, G.S. Тischenko

A.I. Burnasyan Federal Medical Biophysical Center of FMBA, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

I.K. Belyaev – head of Lab, PhD in Biological Sciences; A.S. Samoylov – General Director SRC-FMBC, MD; E.S. Zhorova – leading researcher, PhD in Biological Sciences; V.S. Kalistratova – leading researcher, MD; I.M. Parfenov – research fellow; G.S. Tischenko – research fellow

Abstract

Purpose: Investigation of macro and micro distribution of 239PuO2 in the lungs of rats and metabolic parameters taking into account the variability of initial bronchoalveolar deposits.

Materials and methods: Plutonium dioxide was single introduced intracheal into nonlinear male rats in the amount of 100 kBq / kg of body weight. The experimental animals were observed during their life. Lifetime measurement of radioactivity of the body and excreta and posthumous radiometry of organs were made. Auto and histoautoradiografic study of lungs and lymph nodes were performed.

Results: 239PuO2 particles are removed from the respiratory organs most intensively during the first 7 days. Slowing of metabolic processes is observed in the period from 7 to 200 days. The data on post-mortem 239PuO2 content in the lungs and regional lymph nodes of rats indicate a decrease of the content of plutonium dioxide in the lungs and no reduction in the lymph nodes with time.

Three periods of effective half-life of plutonium dioxide from the lungs were experimentally identified and calculated. These values indicate that the parameters of the respiratory clearance depend on the value of the initial radionuclide bronchoalveolar deposits.

Conclusions: Сonsiderable variability of plutonium dioxide content in the lungs and regional lymph nodes of rats following intratracheal administration has been shown. Neven distribution of 239PuO2 with the expressed α-particle aggregation assumes a significant difference in the local fabric of absorbed radiation doses in the lungs, but does not exclude the possibility of their calculation on the respiratory system as a whole. Options clearance from the respiratory 239PuO2 correspond to the values of the initial bronchoalveolar deposits.

The cleansing light of plutonium dioxide, in contrast to its soluble compounds, the role of radionuclide transport blood to other organs and tissues is not of great impotance.

The results presented plutonium dioxide metabolism studies administered intratracheally, testifies to the fact that the implementation of the biological effects of the compounds can be expected mainly in the lungs. Evidence about the profile respiratory disease will be presented in a subsequent communication.

Key words: plutonium dioxide, lungs, metabolism

REFERENCES

  1. Buldakov L.A., Vasilenko I.Ja., Kalistratova V.S. et al. Radionukidy i proizvodstvennaja dejatel’nost’ cheloveka. Moscow: 1999. 160 p. (In Russ.).
  2. Vasilenko I.Ja., Vasilenko O.I. Plutonij. Jenergija: jekonomika, tehnika, jekologija. 2004. No. 1. P. 60–63. (In Russ.).
  3. Radiacionnaja bezopasnost’. In: Akademika RAMN Il’in L.A. (ed.). Moscow: Izd.AT. 2005. 416 p.
  4. Buldakov L.A., Ljubchanskij Je.R., Moskalev Ju.I., Nifatov A.P. Problemy toksikologii plutonija. Moscow: Atomizdat. 1969. 268 p. (In Russ.).
  5. Ljubchanskij Je.R., Kuz’menko O.V., Osovec S.V., Sokolova S.N. Prognoznye ocenki metabolizma i kancerogennogo dejstvija α-izluchatelej (234,235U, 237Np, 239Pu, 241Am) v ljogkih i skelete cheloveka: obobshhenie jeksperimental’nyh dannyh, poluchennyh na razlichnyh biologicheskih modeljah. Ozjorsk. 2011. 304 p. (In Russ.).
  6. Moskalev Ju.I., Zalikin G.A., Nisimov P.G. et al. Problemy radiobiologii 238 Moscow: Jenergoatomizdat. 1990. 168 p. (In Russ.).
  7. Biologicheskie jeffekty ingalirovannyh radionuklidov. Publikacija 31 MKRZ. Per. s angl. Pod red. Moiseev A.A. (ed.). Moscow: Atomizdat. 1984. 136 p. (In Russ.).
  8. Beljaev I.K., Elatonceva N.B., Zarajskij A.V., Popov B.A. Kolichestvennye zakonomernosti modeli vnutritraheal’nogo vvedenija v jeksperimente. Radiobiologija. 1988. 28. No. 3. P. 396–400. (In Russ.).
  9. Zalikin G.A., Nisimov P.G., Zhukova I.V. Metabolizm i toksichnost’ 238Pu pri intratraheal’nom vvedenii. Itogovaja konferencija o nauchno-tehnicheskom sotrudnichestve v oblasti radiacionnoj bezopasnosti mezhdu Ministerstvom Zdravoohranenija SSSR i Gosudarstvennym upravleniem po atomnoj bezopasnosti i zashhite ot izluchenija v period 1976–1978 g.g., Vladimir, 28 avgusta – 1 sentjabrja 1978. 1979 g. P. 30–37. (In Russ.).
  10. Zhorova E.S., Zalikin G., Nisimov P.G. Gistopatologija legkih krys pri porazhenii 238. Radiobiologija. 1989. 29. Vol. 2. P. 202–206. (In Russ.).
  11. Вrain J.D., Knutson D.E., Sorokin S.P. et al. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 1976. Vol. 11. P. 13–33.
  12. Bochvar I.A., Pashkova T.A. Rekomendacii po opredeleniju aktivnosti plutonija-239 v probah organov i tkanej jeksperimental’nyh zhivotnyh s pomoshh’ju avtomaticheskogo zhidkostnogo schetchika Del’ta-300, IBF MZ SSSR, inv. No. R-362, Moscow: 1984, 5 p. (In Russ.).
  13. Sanders C.L. Inhalation toxicology of 238PuO2 and 239PuO2 in sirian golden hanster. Radiat. Res. 1977. Vol. 70. P. 333–344.

For citation: Belyaev IK, Samoylov AS, Zhorova ES, Kalistratova VS, Parfenova IM, Tischenko G.S. Dioxide plutonium-239 in the lung. Report 1: Metabolism 239PuO2 with intratracheal administration. Medical Radiology and Radiation Safety. 2017;62(2):12-9. Russian. DOI: 10.12737/25029

PDF (RUS) Full-text article (in Russian)

Medical Radiology and Radiation Safety. 2017. Vol. 62. No.  6. P. 5-11

RADIATION BIOLOGY

DOI: 10.12737/article_5a251c065ed543.22688556

Radiosensitizing Effect of Niclosamide on Cancer Stem Cells of the Human Mammary Adenocarcinoma MCF-7 Cell Line

V.G. Shuvatova, A.P. Kuvyrchenkova, Yu.P. Semochkina, E.Yu. Moskaleva

National Research Centre “Kurchatov Institute”, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

V.G. Shuvatova – Research Engineer; A.P. Kuvyrchenkova – Research Assistant; Yu.P. Semochkina – Research Assistant; E.Yu. Moskaleva – Leading Researcher, Dr. Sc. Biol., Prof.

Abstract

Purpose: To investigate the effect of niclosamide on the radiosensitivity of MCF-7 cancer stem cells (CSC) and to explore the molecular mechanism of radiosensitization.

Material and methods: Cancer stem cells were obtained from MCF-7 mammary adenocarcinoma monolayer culture (2D) and propagated as mammospheres (3D) in serum-free DMEM/F12 supplemented with EGF, bFGF, B 27, heparin, and insulin in ultra-low attachment plates. The single cell suspensions were irradiated with 1, 2, 4, 6, and 8 Gy using 60Co source at a dose rate of 0.54 Gy/min. Controls were sham irradiated. The size of the CD44+/CD24-/low CSC fraction was measured using flow cytometry at the 7th and 14th days after irradiation. The radiosensitizing effect of niclosamide on the 2D- and 3D-cell cultures was assessed by the number of cells at the 7th and 14th days after irradiation with doses of 2 or 4 Gy. Niclosamide was added to the cell cultures in a dose of 2 µM 1 h before irradiation. Media with niclosamide were changed to corresponding media without niclosamide 24 h post-irradiation. Cell survival was evaluated by hemocytometer cell counting using trypan blue. The size of the CSC fraction was measured at the 7th day after the irradiation with or without niclosamide. To investigate the effect of niclosamide on DNA damage the level of histone γH2AX was measured by flow cytometry at 60 min after irradiation.

Results: Culturing adherent MCF-7 cells line under non-adherent mammosphere-forming conditions led to significantly increase in CSCs proportion. CD44+/CD24–/low cell fraction in 2D-culture was 0.2 ± 0.1 %, and it was 3.2 ± 0.6 % in 3D-culture (the third-generation spheres). Subpopulation of CSCs increased with the increase in irradiation dose. At day 14 after irradiation with the dose of 8 Gy, CD44+/CD24–/low cell fraction in 2D-culture was 2.2 ± 0.6 %, and it was 12.0 ± 0.9 % in 3D-culture. Cells grown in mammosphere-culture were found to have a higher survival rate after irradiation at doses of 2 and 4 Gy than cells grown in adherent conditions. At day 7 after irradiation with 2 and 4 Gy the 3D-culture cells count decreased less than the 2D-culture cells counts (92 ± 13 % and 61 ± 10 % versus 58 ± 4 % and 37 ± 3 % compared to non-irradiated control). Moreover, cells grown in mammosphere-culture showed a higher renewal capacity. At day 14 after irradiation with 2 and 4 Gy the number of 3D-culture cells was 66 ± 11 % and 30 ± 7 % while the number of adherent cells was 43 ± 2 % and 7 ± 1 % compared to non-irradiated control. It was found that niclosomide has radiosensitizing effect on cells grown in mammospheres. Pretreatment with niclosamide 1 h prior to irradiation resulted in decrease in cell survival. At day 7 after irradiation at 2 and 4 Gy in the presence of niclosamide, the numbers of 3D-culture cells were reduced by 13 % and 7 % compared to their numbers after irradiation with appropriate doses in the absence of niclosamide. Furthermore, niclosamide was shown to reduce the percentage of CSCs. At day 7 after irradiation with 2 and 4 Gy, 3D-culture showed elevated percentages of CD44+/CD24−/low cells: CSC fraction in mammospheres were 4.6 ± 0.3 % and 6.1 ± 0.5 %, respectively, and after pretreatment by niclosamide and irradiation the sizes of the CSC fractions were 2.5 ± 0.1 % and 4.0 ± 0.3 %, respectively. Radiosensitizing effect of niclosamide lasted for 2 weeks. At day 14 after irradiation at 2 and 4 Gy in combination with niclosamide the numbers of 3D-culture cells were reduced by 13 % and 9 % compared to cell numbers after irradiation with appropriate doses without of niclosamide. Radiosensitization of cells grown in mammospheres might be related with increase in DNA double-strand breaks (DSB) prodused by niclosomide. At 1 h after 2 and 4 Gy irradiation cells grown in mammospheres shown 2.4-fold and 4.8-fold increase in DNA DSB, as indicated by γH2AX levels, compared to baseline. The combined treatment of niclosamide and irradiation with 2 and 4 Gy resulted in 3.4-fold and 5.5-fold increase in the levels of histone γ-H2AX, respectively.

Conclusion: Niclosamide increased the radiosensetivity not only of the bulk cells of mammary adenocarcinoma line MCF-7 but also of CSCs. The radiosensitizing effect of niclosamide was associated with increase in the level of DNA damage.

Key words: niclosamide, γ-radiation, MCF-7 cell line, cancer stem cells, human breast adenocarcinoma, radioresistance, radiosensitization

REFERENCES

  1. Li F., Tiede B., Massagué J. et al. Beyond tumorigenesis: cancer stem cells in metastasisю Cell Research. 2007. Vol. 17. P. 3–14.
  2. Al-Hajj M., Wicha M.S., Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cellsю Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. No. 7. P. 3983–3988.
  3. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questionsю Nat. Rev. Cancer. 2008. Vol. 8. No. 10. P. 755–768.
  4. Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalю Cancer Cell Int. 2005. Vol. 5. P. 30–38.
  5. Krause M., Dubrovska A., Linge A. et al. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatmentsю Adv. Drug Deliv. Rev. 2017. Vol. 109. P. 63–73.
  6. Krause M., Yaromina A., Eicheler W. et al. Cancer stem cells: targets and potential biomarkers for radiotherapyю Clin. Cancer Res. 2011. Vol. 17. No. 23. P. 7224–7229.
  7. Bao S., Wu Q., McLendon R.E. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseю Nature. 2006. Vol. 444. P. 756–760.
  8. Lagadec C., Vlashi E.,Donna L.D. et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatmentю Breast Cancer Res. 2010. Vol. 12. No.1. P. R13–R20.
  9. Peitzsch C., Kurth I., Kunz-Schughart L. et al. Discovery of the cancer stem cell related determinants of radioresistanceю Radiother. Oncol. 2013. Vol. 108. P. 378–387.
  10. Yang T., Rycaj K. Targeted therapy against cancer stem cellsю Oncol. Lett., 2015. Vol. 10. No. 1. P. 27–33.
  11. Lamb R., Harrison H., Hulit J. et al. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibitionю Oncotarget. 2014. Vol. 5. No. 22. P. 11029–11037.
  12. You S., Li R, Park D. Disruption of STAT3 by Niclosamide reverses radioresistance of human lung cancerю Mol. Cancer Ther. 2014. Vol. 13. No. 3. P. 606–616.
  13. Dontu G., Abdallah W.M., Foley J.M. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cellsю Genes Dev. 2003. Vol. 17. No. 10. P. 1253–1270.
  14. Wang R., Lv Q., Meng W. et al. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumorsю J. Thorac. Dis. 2014. Vol. 6. No. 6. P. 829–837.
  15. Krutzik P., Nolan G. Intracellular phosphoprotein staining techniques for flow cytometry: monitoring single cell signaling eventsю Cytometry. Part A. 2003. Vol. 55A. P. 61–70.
  16. Phillips T.M., McBride W.H., Pajonk F. The response of CD24−/low/CD44+ breast cancer-initiating cells to radiationю J. Natl. Cancer Inst. 2006. Vol. 98. No. 24. P. 1777–1785.
  17. Wang Y.C., Chao T.K., Chang C.C. et al. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cellsю PLoS One. 2013. No. 8. P. e74538.
  18. Khanim F.L., Merrick B.A., Giles H.V. et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionю Blood Cancer J. 2011. Vol. 1. No. 10. P. e39.

For citation: Shuvatova VG, Kuvyrchenkova AP, Semochkina YuP, Moskaleva EYu. Radiosensitizing Effect of Niclosamide on Cancer Stem Cells of the Human Mammary Adenocarcinoma MCF-7 Cell Line. Medical Radiology and Radiation Safety. 2017;62(6):5-11. Russian. DOI: 10.12737/article_5a251c065ed543.22688556

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2926527
Today
Yesterday
This week
Last week
This month
Last month
For all time
1544
2221
3765
33458
24823
113593
2926527
Forecast today
2088

Your IP:216.73.216.82
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх